ArticleJAMA oncology2018

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

Nora Pashayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.